Oncology at AstraZeneca: The journey to the top

AstraZeneca’s rise in oncology may turn out to be one of the industry’s big all-time turnaround stories. BioCentury sat down with one of its architects, Susan Galbraith, to discuss the factors behind the pharma’s growth in oncology, and where she sees cancer medicine headed from here.

In the first of a two-part Q&A, Galbraith discusses the critical decision points and the philosophy that has underscored the turnaround. ...